TAK · Takeda Pharmaceutical Company Limited

Summary

Takeda Pharmaceutical Company Limited announced that its Board of Directors approved next steps in the company's transformation, expecting annualized gross savings of more than JPY 200 billion by FY2028 and restructuring expenses of approximately JPY 150 billion in FY2026. These initiatives aim to strengthen competitiveness, offset launch investments, and accelerate growth without impacting FY2025 financial forecasts.

Key takeaways

• Board of Directors approved transformation next steps on March 25, 2026
• Annualized gross savings of more than JPY 200 billion by FY2028
• Restructuring expenses of approximately JPY 150 billion in FY2026
• Lower restructuring expenses anticipated in FY2027 and FY2028
• Prepares for launches including oveporexton, rusfertide, and zasocitinib
• No significant impact on FY2025 full-year consolidated financial forecast